BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer

Core Viewpoint - BioVaxys Technology Corp. announced positive results from a phase 1 clinical study of maveropepimut-S (MVP-S) combined with neoadjuvant hormone therapy for women with hormone receptor positive HER2 negative (HR+HER2-) stage II-III breast cancer, indicating a promising treatment avenue in this patient population [1][7]. Clinical Study Results - The clinical study showed that MVP-S in combination with letrozole generated a strong immune response in participants with HR+HER2- stage II-III breast cancer [2]. - All three patients in the study experienced at least a 50% decrease in Ki67 levels, a marker for cancer cell proliferation, from a median of 24% before treatment to a median of 6% after treatment [6]. Market Potential - The global market for HER2-negative breast cancer was valued at $14.4 billion in 2024 and is projected to reach $21.5 billion by 2030, with HR+/HER2- tumors representing approximately 57.77% of the total revenue share in 2024 [3]. Technology Platform - BioVaxys' DPX platform is a novel liposome-based delivery system designed to create long-lasting, targeted immune responses without releasing active ingredients at the injection site, enhancing the efficiency of immune cell programming [4]. Future Plans - BioVaxys plans to further evaluate the systemic immunity of MVP-S and conduct expanded profiling of biopsy samples compared to post-treatment surgical samples, aiming to pursue a phase II study to modify the tumor immune environment in high-risk HR+ breast cancer [7].